SLURP-2 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of SLURP-2 (Secreted Ly6/uPAR-Related Protein 2), a member of the Ly6/uPAR superfamily. SLURP-2 is a small, secreted protein predominantly expressed in epithelial tissues such as the skin and mucous membranes. It plays a significant role in modulating various cellular processes, including cell proliferation, differentiation, and immune responses. SLURP-2 functions as a ligand for nicotinic acetylcholine receptors (nAChRs), particularly the α7 subtype, influencing intracellular signaling pathways that affect keratinocyte behavior and epidermal homeostasis. By interacting with these receptors, SLURP-2 can regulate calcium influx, gene expression, and cytokine release, thereby impacting cell communication and function within epithelial layers.
Inhibitors of SLURP-2 work by interfering with its ability to bind to nAChRs or by disrupting its structural integrity, thus modulating downstream signaling pathways. These compounds may bind directly to SLURP-2, preventing it from associating with its receptors, or they might block the receptor sites to hinder SLURP-2 binding. By inhibiting SLURP-2, these substances can alter cellular processes such as proliferation and differentiation, potentially affecting the balance of cell growth and maturation in epithelial tissues. Research into SLURP-2 inhibitors provides valuable insights into the molecular mechanisms underlying cell signaling in the skin and other epithelial tissues, enhancing the understanding of how proteins like SLURP-2 contribute to the regulation of cellular function and tissue homeostasis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
An immunomodulatory drug that may affect SLURP2 activity indirectly through its anti-inflammatory properties. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
An immunosuppressant that could modulate immune-related pathways and potentially influence SLURP2 activity. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
An immunosuppressive agent that might alter immune responses, potentially affecting SLURP2-associated processes. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A kinase inhibitor that targets multiple pathways and could indirectly influence SLURP2 activity via anti-cancer mechanisms. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that may impact SLURP2 activity through immune regulation and anti-proliferative effects. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Has immunomodulatory effects that could indirectly affect SLURP2 through modulation of inflammatory responses. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that could influence cellular pathways associated with SLURP2 activity in the context of cancer. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
An immunomodulatory drug that might affect SLURP2 by modulating the immune microenvironment. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
A Bruton's tyrosine kinase inhibitor that may indirectly impact SLURP2 activity through immune pathway modulation. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Targets BRAF V600E mutation, potentially affecting pathways associated with SLURP2 in melanoma. | ||||||